SKYEPHARMA PLC
Form 6-K
September 07, 2005

**SECURITIES AND EXCHANGE COMMISSION**
**WASHINGTON, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**
**PURSUANT TO RULE 13a - 16 OR 15d - 16 OF**
**THE SECURITIES EXCHANGE ACT OF 1934**

For the month of September, 2005

SkyePharma PLC

(Translation of registrant's name into English)

SkyePharma PLC, 105 Piccadilly, London W1J 7NJ England

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.

Form 20-F X Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No X

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-
_____

**For Immediate Release**

**SkyePharma PLC**

**FORADIL® CERTIHALER LAUNCHED IN GERMANY**

LONDON, UK, 7 September 2005 -- SkyePharma PLC (Nasdaq: SKYE; LSE: SKP) announces today (Novartis) has launched FORADIL® CERTIHALER (formoterol fumarate inhalation powder) on the Ger and chronic obstructive pulmonary disease (COPD). The German pharmaceutical regulatory autho June. FORADIL® CERTIHALER is a trademark of Novartis. FORADIL® CERTIHALER , co-developed submitted for regulatory review in Europe on a country-by-country basis beginning in Decemb Switzerland, Austria, Finland, Portugal and the Netherlands as well as in Germany. It has also Latin America and in South Africa. FORADIL® CERTIHALER was also submitted for regulatory rev Food and Drug Administration (FDA) has assessed the product as "approvable" and Novartis has pr that were requested. The US FORADIL® franchise has been licensed by Novartis to Schering-Plough C

Michael Ashton, SkyePharma's Chief Executive Officer, commented: "We are delighted that FOR market in Germany, and we expect patients to appreciate the design features in this sophisticated

FORADIL® CERTIHALER embodies two proprietary SkyePharma technologies, the SKYEHALER , a novel inhaler ("MDDPI") device, and SKYEPROTECT , a powder formulation that protects the drug from a stability and dose-to-dose reproducibility.

Formoterol, the active ingredient in FORADIL® CERTIHALER , is a long-acting beta2-agonist bron of action (within 5 minutes) with a long-lasting bronchodilation effect for 12 hours. This fe patients who suffer from asthma and COPD. The breath-actuated FORADIL® CERTIHALER dry-powde patients the convenience of 30 days of therapy in a single inhaler. This evolution of the FO valuable and convenient option for asthma and COPD patients who require maintenance therapy with

SkyePharma will earn a royalty on future sales of FORADIL® CERTIHALER in all markets. SkyePha FORADIL® CERTIHALER .

**For further information please contact:**

| | |
|---|---|
| **SkyePharma PLC** | **+44 207 491 1777** |
| Michael Ashton, Chief Executive Officer | |
| Peter Laing, Director of Corporate Communications | **+44 205 491 5124** |
| Sandra Haughton, US Investor Relations | **+1 212 753 5780** |
| **Buchanan Communications** | **+44 207 466 5000** |
| Tim Anderson / Mark Court / Rebecca Skye Dietrich | |


**Notes to Editors**

**SkyePharma PLC** develops pharmaceutical products benefiting from world-leading drug delivery te and more effective drug formulations. There are now eleven approved and marketed products incorp the areas of oral, injectable, inhaled and topical delivery, supported by advanced solubilisatio visit www.skyepharma.com.

*Certain statements in this news release are forward-looking statements and are made in reliance U.S. Private Securities Litigation Act of 1995. Although SkyePharma believes that the expectatio statements are reasonable, it can give no assurance that these expectations will materialize. B risks and uncertainties, actual results may vary significantly from those expressed or impli based upon a number of factors, which are described in SkyePharma's 20-F and other documents on cause differences between actual results and those implied by the forward-looking statements c without limitation, risks related to the development of new products, risks related to obtainin for existing, new or expanded indications of existing and new products, risks related to SkyePh on a large scale or at all, risks related to SkyePharma's and its marketing partners' ability maintain or expand market share in the face of changes in customer requirements, competition an to regulatory compliance, the risk of product liability claims, risks related to the ownership risks related to SkyePharma's ability to manage growth. SkyePharma undertakes no obliga forward-looking statement to reflect events or circumstances after the date of this release.*

END

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**SkyePharma PLC**

By: /s/ Douglas Parkhill

Name: Douglas Parkhill
Title: Company Secretary

Date: September 7, 2005